Lead Product(s) : BAT6026,Sodium Chloride
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bio-Thera Solutions Announces Phase IB / IIA Trial for Bat6026 in Atopic Dermatitis
Details : BAT6026 is a novel OX40 agonist antibody being evaluated in phase 1/2 trials combined with sodium chloride injection for moderate to severe atopic dermatitis treatment.
Product Name : BAT6026
Product Type : Antibody
Upfront Cash : Inapplicable
January 02, 2024
Lead Product(s) : BAT6026,Sodium Chloride
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.
Product Name : KX-826
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 16, 2021
Lead Product(s) : Pyrilutamide
Therapeutic Area : Dermatology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable